Search

Pyrantel

Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900]. … Pyrantel has shown to be effective after a single dose [L1905]. In humans, it is administered as pyrantel pamoate [A32282],[A32283],[L1893],[L1898].

Probucol

A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

Landiolol

[A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity … [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November

Zanidatamab

Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

Levamlodipine

Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. … [L10833] This medication was first marketed in Russia and India before being granted FDA approval.

Chloric acid

Cinoxate

Metyrapone

An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

Gadoquatrane

in the central nervous system and in the body. … [L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity

Tucatinib

Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … [L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]